Document Detail


From biochemical principles of apoptosis induction by TRAIL to application in tumour therapy.
MedLine Citation:
PMID:  19142621     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily which has been shown to selectively kill tumour cells, while sparing normal tissue. This attribute makes TRAIL an attractive drug candidate for cancer therapy. Although most primary tumour cells turned out to be primarily TRAIL-resistant, recent studies evidenced that a variety of cancers can be sensitised to TRAIL-induced apoptosis upon pre-treatment with chemotherapeutic agents or irradiation, while normal cells remain TRAIL-resistant. However, biomarkers that reliably predict which patients may benefit from such combinatorial therapies are required. Thus, it is essential to better understand the mechanisms underlying TRAIL resistance versus sensitivity. In this chapter, we introduce the signalling events which take place during TRAIL-induced apoptosis, describe the physiological function of TRAIL and summarise pre-clinical and clinical results obtained so far with TRAIL-receptor agonists.
Authors:
Stefanie M Cordier; Kerstin Papenfuss; Henning Walczak
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Results and problems in cell differentiation     Volume:  49     ISSN:  0080-1844     ISO Abbreviation:  Results Probl Cell Differ     Publication Date:  2009  
Date Detail:
Created Date:  2010-02-19     Completed Date:  2010-03-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0173555     Medline TA:  Results Probl Cell Differ     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  115-43     Citation Subset:  IM    
Affiliation:
Tumour Immunology Unit, Division of Medicine, Imperial College, London, W12 0NN, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Apoptosis / drug effects*
Drug Resistance, Neoplasm / drug effects*
Humans
Neoplasms / metabolism,  therapy*
Receptors, TNF-Related Apoptosis-Inducing Ligand / agonists,  metabolism
Signal Transduction / drug effects*
TNF-Related Apoptosis-Inducing Ligand / metabolism,  therapeutic use*
Chemical
Reg. No./Substance:
0/Receptors, TNF-Related Apoptosis-Inducing Ligand; 0/TNF-Related Apoptosis-Inducing Ligand; 0/TNFSF10 protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Are the guidelines correct? Should all patients with coronary heart disease or diabetes be treated w...
Next Document:  Autophagy in Cancer and Chemotherapy.